Intracerebral hemorrhage: A review of coagulation function

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 6, 2013, Pages 652-662

  Emiru, Tenbit ^a   Bershad, Eric M ^b   Zantek, Nicole D ^c   Datta, Yvonne H ^c   Rao, Gundu H R ^c   Hartley, Eliza W ^a   Divani, Afshin A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

bleeding diathesis; clinical outcome; hematoma expansion; intracerebral hemorrhage; platelet dysfunction

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; APIXABAN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 9 COMPLEX; D DIMER; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FRESH FROZEN PLASMA; GLIAL FIBRILLARY ACIDIC PROTEIN; HIGH DENSITY LIPOPROTEIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; NASARUPLASE BETA; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

AGING; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; HEMATOMA; HEMATOMA EXPANSION; HEMOSTASIS; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VASCULAR AMYLOIDOSIS;

BLEEDING DIATHESIS; CLINICAL OUTCOME; HEMATOMA EXPANSION; INTRACEREBRAL HEMORRHAGE; PLATELET DYSFUNCTION;

ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; CEREBRAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887962412     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612454938     Document Type: Article

References (78)

1. Cheung RT. Update on medical and surgical management of intracerebral hemorrhage. Rev Recent Clin Trials. 2007 ; 2 (3). 174-181
2. Kase CS. Advances in intracerebral haemorrhage management. Eur J Anaesthesiol Suppl. 2008 ; 42: 16-22
3. Santalucia P. Intracerebral hemorrhage: medical treatment. Neurol Sci. 2008 ; 29 (suppl 2). S271 - S273
4. Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke. 2009 ; 40 (4). 1533-1538
5. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007 ; 82 (1). 82-92
6. Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol. 2010 ; 30 (5). 565-572
7. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006 ; 37 (1). 256-262
8. Shah QA, Ezzeddine MA, Qureshi AI. Acute hypertension in intracerebral hemorrhage: pathophysiology and treatment. J Neurol Sci. 2007 ; 261 (1-2). 74-79
9. Pezzini A, Padovani A. Cerebral amyloid angiopathy-related hemorrhages. Neurol Sci. 2008 ; 29 (suppl 2). S260 - S263
10. Samandouras G, Teddy PJ, Cadoux-Hudson T, Ansorge O. Amyloid in neurosurgical and neurological practice. J Clin Neurosci. 2006 ; 13 (2). 159-167
11. Opeskin K. Cerebral amyloid angiopathy. A review. Am J Forensic Med Pathol. 1996 ; 17 (3). 248-254
12. Aguilar MI, Freeman WD. Spontaneous intracerebral hemorrhage. Semin Neurol. 2010 ; 30 (5). 555-564
13. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010 ; 376 (9735). 112-123
14. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology. 2006 ; 66 (2). 165-171
15. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain. 2007 ; 130 (pt 8). 1988-2003
16. Gregoire SM, Jager HR, Yousry TA, Kallis C, Brown MM, Werring DJ. Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry. 2010 ; 81 (6). 679-684
17. Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med. 2003 ; 3 (3). 271-278
18. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008 ; 39 (11). 2993-2996
19. Zubkov AY, Mandrekar JN, Claassen DO, Manno EM, Wijdicks EF, Rabinstein AA. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008 ; 65 (10). 1320-1325
20. Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost. 2003 ; 89 (2). 278-283
21. Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008 ; 71 (14). 1084-1089
22. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 (12). 1139-1151
23. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 (11). 981-992
24. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 (10). 883-891
25. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke. 2012 ; 43 (6). 1511-1517
26. Gonzalez-Duarte A, Garcia-Ramos GS, Valdes-Ferrer SI, Cantu-Brito C. Clinical description of intracranial hemorrhage associated with bleeding disorders. J Stroke Cerebrovasc Dis. 2008 ; 17: 204-207
27. Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009 ; 40 (7). 2398-2401
28. Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE. Prior antiplatelet use does not affect hemorrhage growth or outcome after ich. Neurology. 2009 ; 72: 1397-1402
29. Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol. 2003 ; 25 (8). 660-664
30. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med. 1995 ; 333 (24). 1581-1587
31. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 ; 359 (13). 1317-1329
32. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA. 1999 ; 282 (21). 2003-2011
33. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001 ; 57 (9). 1603-1610
34. Kakar P, Lip GY. Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. Expert Rev Cardiovasc Ther. 2007 ; 5 (3). 441-450
35. Lip GY. Hypertension and the prothrombotic state. J Hum Hypertens. 2000 ; 14 (10-11). 687-690
36. Lip GY, Li-Saw-Hee FL. Does hypertension confer a hypercoagulable state?. J Hypertens. 1998 ; 16 (7). 913-916
37. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des. 2003 ; 9 (21). 1715-1732
38. Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation. 2000 ; 101 (3). 264-269
39. Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011 ; 76 (14). 1238-1244
40. Ji N, Lu JJ, Zhao YL, Wang S, Zhao JZ. Imaging and clinical prognostic indicators for early hematoma enlargement after spontaneous intracerebral hemorrhage. Neurol Res. 2009 ; 31 (4). 362-366
41. Chen ST, Chen SD, Hsu CY, Hogan EL. Progression of hypertensive intracerebral hemorrhage. Neurology. 1989 ; 39 (11). 1509-1514
42. Broderick JP, Brott TG, Tomsick T, Barsan W, Spilker J. Ultra-early evaluation of intracerebral hemorrhage. J Neurosurg. 1990 ; 72 (2). 195-199
43. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996 ; 27 (10). 1783-1787
44. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997 ; 28 (1). 1-5
45. Mayer SA, Brun NC, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage US Phase IIA trial. Neurocrit Care. 2006 ; 4 (3). 206-214
46. Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke. 2005 ; 36 (1). 74-79
47. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005 ; 352 (8). 777-785
48. Diringer MN, Skolnick BE, Mayer SA, et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke. 2008 ; 39 (3). 850-856
49. Diringer MN, Skolnick BE, Mayer SA, et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the factor seven for acute hemorrhagic stroke (FAST) trial. Stroke. 2010 ; 41 (1). 48-53
50. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008 ; 358 (20). 2127-2137
51. Birchall J, Stanworth SJ, Duffy MR, Doree CJ, Hyde C. Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia. Transfus Med Rev. 2008 ; 22 (3). 177-187
52. Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care. 2010 ; 12 (3). 403-413
53. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor Hemostatic therapy with rFVIIa prevents hematoma expansion, but does not improve clinical outcome. a in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005 ; 2 (3). 263-267
54. Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? Ash evidence-based review 2008. Hematology Am Soc Hematol Educ Program. 2008 ;: 36-38
55. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood. 2010 ; 116 (5). 693-701
56. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010 ; 8: 149-154
57. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology. 2008 ; 109 (5). 918-926
58. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007 ; 121 (1). 9-16
59. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005 ; 115 (6). 455-459
60. Imberti D, Barillari G, Biasioli C, et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus. 2011 ; 9 (2). 148-155
61. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009 ; 49 (6). 1171-1177
62. Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care. 2008 ; 8 (1). 36-41
63. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006 ; 37 (6). 1465-1470
64. Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg. 2012 ; 116 (3). 491-497
65. Lauer A, Cianchetti FA, Van Cott EM, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation. 2011 ; 124 (15). 1654-1662
66. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011 ; 42 (12). 3594-3599
67. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011 ; 124 (14). 1573-1579
68. Ducruet AF, Hickman ZL, Zacharia BE, et al. Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurol Res. 2010 ; 32 (7). 706-710
69. Naidech AM, Liebling SM, Rosenberg NF, et al. Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. Neurocrit Care. 2012 ; 16 (1). 82-87
70. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology. 2009 ; 73 (5). 393-399
71. Marti-Fabregas J, Borrell M, Silva Y, et al. Hemostatic proteins and their association with hematoma growth in patients with acute intracerebral hemorrhage. Stroke. 2010 ; 41 (12). 2976-2978
72. Takahashi H, Urano T, Nagai N, Takada Y, Takada A. Progressive expansion of hypertensive intracerebral hemorrhage by coagulopathy. Am J Hematol. 1998 ; 59 (2). 110-114
73. Fujii Y, Tanaka R, Takeuchi S, Koike T, Minakawa T, Sasaki O. Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg. 1994 ; 80 (1). 51-57
74. Rodriguez-Luna D, Rubiera M, Ribo M, et al. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage. Stroke. 2011 ; 42 (9). 2447-2452
75. Delgado P, Alvarez-Sabin J, Abilleira S, et al. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology. 2006 ; 67 (1). 94-98
76. Alexandrova ML, Danovska MP. Serum C-reactive protein and lipid hydroperoxides in predicting short-term clinical outcome after spontaneous intracerebral hemorrhage. J Clin Neurosci. 2011 ; 18 (2). 247-252
77. Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry. 2006 ; 77 (2). 181-184
78. Johansson L, Jansson JH, Stegmayr B, Nilsson TK, Hallmans G, Boman K. Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study. Stroke. 2004 ; 35 (4). 826-830